Halo Labs Unveils Aura+ Subscription Program for Convenient and Affordable Particle Analysis See more here
Read More
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023 ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint - The ENB-003 in combination with KEYTRUDA® (pembrolizumab)…
Read More
SIRPant Immunotherapeutics Appoints Jelle Kijlstra, MD, MBA as Chief Medical Officer Accomplished healthcare executive brings extensive drug development and regulatory experience from global CRO and multiple pharmaceutical companies to SIRPant Immunotherapeutics Inc See more here
Read More
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies - The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities - Clay B.…
Read More
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors First dual-specific PD-L1/PD-L2 antibody with killing function designed to treat the many immune-excluded cancers that are resistant to existing immunotherapies Phase 1b will focus on tumors that are…
Read More
Melior Is Selected as a Top 20 CRO by Pharma Tech Outlook - Melior has cover appearance on this industry-leading magazine - Melior is recognized for the combination of its attention to quality, culture and, innovative offering See more here
Read More
VESTECK , Inc. is excited to announce that the U.S. Patent Application No. 17/841,373 Title: REMOTE SURGICAL SUTURE SYSTEM, has been allowed by the U.S. Patent and Trademark Office (USPTO) See more here
Read More
VESTECK Continues to Help Patients Around the World See more here
Read More
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity See more here
Read More
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results See more here
Read More